Torthaí cuardaigh - Ruby Wu

Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer de réir Tizita Zeleke, Qingfei Pan, Codruța Chiuzan, Maika Onishi, Yuxin Li, Haiyan Tan, Mariano J. Alvarez, Erin Honan, Min Yang, Pei Ling Chia, Partha Mukhopadhyay, Sean Kelly, Ruby Wu, Kathleen Fenn, Meghna S. Trivedi, Melissa Accordino, Katherine D. Crew, Dawn L. Hershman, Matthew Maurer, Simon Jones, Anthony A. High, Junmin Peng, Andrea Califano, Kevin Kalinsky, Jiyang Yu, Jose Silva

Faigh an téacs iomlán